Axsome Therapeutics Inc (AXSM)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

200 BROADWAY, 3RD FLOOR NEW YORK, NY 10038

Axsome Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The Company focuses on developing therapies for the management of pain, neurological disorders, and other central nervous system. Axsome Therapeutics serves patients worldwide.

Data as of 2020-06-27
Market Cap3.181 Billion Shares Outstanding37.076 Million Avg 30-day Volume581.217 Thousand
P/E Ratio Dividend Yield EPS-2.57
Price/Sales Price cash flow ratio Price free cash flow ratio-47.2
Book Value4.21 Price to Tangible Book18.19 Alpha
Short Interest Ratio % Short Interest to Float R-squared
BETA 52-week High/Low109.94 / 13.64 Stddev
View SEC Filings from AXSM instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 8 7 (0.46%)
13F Filers holding this stock: 160 59 (3.86%)
Aggregate 13F shares on 03/31/2020: 22.202 Million 13.139 Million
Aggregate 13F shares on 12/31/2019: 22.27 Million 10.677 Million
Percent change: -0.31% 23.07%
Funds creating new positions: 42 19
Funds Adding to an existing position: 63 24
Funds closing out their position: 43 16
Funds reducing their position: 41 15
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding AXSM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AXSM BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

1.4 Thousand total shares from 2 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

COLEMAN MARK

  • Director
408,798 2020-06-29 3

PIZZIE NICK CHIEF FINANCIAL OFFICER

  • Officer
41,277 2020-06-29 4

JEFFS ROGER

  • Director
0 2020-06-19 3

SAAD MARK E

  • Director
0 2020-06-05 2

TABUTEAU HERRIOT CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
  • 10% Owner
0 2020-03-17 2

MAREK DAVID C CHIEF COMMERCIAL OFFICER

  • Officer
0 2020-03-17 4

JACOBSON MARK L. CHIEF OPERATING OFFICER

  • Officer
0 2020-03-17 2

POTTER MYRTLE S

  • Director
12,480 2020-01-10 0

GOLUBIESKI JOHN CHIEF FINANCIAL OFFICER

  • Officer
0 2017-08-04 0

AMES CONSTANCE VICE PRESIDENT, FINANCE

  • Officer
0 2017-03-15 0

KAYE RANDALL CHIEF MEDICAL OFFICER

  • Officer
6,022 2015-12-23 0

ANTECIP CAPITAL LLC

  • 10% Owner
7,344,500 2015-11-19 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

COLEMAN MARK - Director

2020-06-29 P 650 $78.50 a 403,698 408,798.00 direct

PIZZIE NICK - Officer CHIEF FINANCIAL OFFICER

2020-06-29 P 777 $76.64 a 41,217 41,277.00 direct

COLEMAN MARK - Director

2020-06-05 A 13,000 a 13,000 0.00 direct

JEFFS ROGER - Director

2020-06-05 A 13,000 a 13,000 0.00 direct

SAAD MARK E - Director

2020-06-05 A 13,000 a 13,000 0.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments